Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Carlos Martinez, MPH, Lauren Carruth, PhD, Hannah Janeway, MD, Lahra Smith, PhD, Katharine M. Donato, PhD, Carlos Piñones-Rivera, PhD, James Quesada, PhD, and Seth M. Holmes, MD, PhD
AMA J Ethics. 2022;E275-282. doi:
10.1001/amajethics.2022.275.